Deucrictibant
Sponsors
Pharvaris Netherlands B.V.
Conditions
Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)C1 Esterase Inhibitor DeficiencyC1 Esterase Inhibitor [C1-INH] DeficiencyC1 Esterase Inhibitor, Deficiency ofC1 Inhibitor DeficiencyHAE With Normal C1 Esterase InhibitorHereditary AngioedemaHereditary Angioedema (HAE)
Phase 2
Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
CompletedNCT04618211
Start: 2021-02-03End: 2023-03-01Updated: 2025-12-17
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
Enrolling by invitationNCT05396105
Start: 2022-12-28End: 2027-06-01Target: 150Updated: 2026-07-21
Phase 3
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Active, not recruitingNCT06669754
Start: 2024-12-01End: 2026-08-01Target: 81Updated: 2026-02-13
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
RecruitingNCT06679881
Start: 2025-02-01End: 2028-12-01Target: 170Updated: 2026-09-01
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
RecruitingNCT07266805
Start: 2025-10-16End: 2027-06-01Target: 32Updated: 2026-06-29